Evidence map›Paper›PMID 27873319›Full record

ArticleThe Journal of pathology2017

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Michele Simbolo, Andrea Mafficini, Katarzyna O Sikora, Matteo Fassan, Stefano Barbi, Vincenzo Corbo, Luca Mastracci, Borislav Rusev, Federica Grillo, Caterina Vicentini and 11 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 225 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.Virchows Archiv : an international journal of pathology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  18. Article
  19. Article
  20. Small cell lung cancer and neuroendocrine tumours.Breathe (Sheffield, England) · 2024
    Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Michele SimboloARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Andrea MafficiniARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Katarzyna O SikoraARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Matteo FassanARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Stefano BarbiDepartment of Diagnostics and Public Health, Section of Anatomical Pathology, University and Hospital Trust of Verona, Verona, Italy.
Vincenzo CorboARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Luca MastracciDepartment of Surgical and Diagnostic Sciences (DISC), University of Genova and IRCCS S. Martino-IST University Hospital, Genoa, Italy.
Borislav RusevARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Federica GrilloDepartment of Surgical and Diagnostic Sciences (DISC), University of Genova and IRCCS S. Martino-IST University Hospital, Genoa, Italy.
Caterina VicentiniARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Roberto FerraraDepartment of Medicine, Section of Medical Oncology, University and Hospital Trust of Verona, Verona, Italy.
Sara PilottoDepartment of Medicine, Section of Medical Oncology, University and Hospital Trust of Verona, Verona, Italy.
Federico DaviniUnit of Thoracic Surgery, University and Hospital Trust of Pisa, Pisa, Italy.
Giuseppe PelosiDepartment of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milano, Italy.
Rita T LawlorARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Marco ChilosiDepartment of Diagnostics and Public Health, Section of Anatomical Pathology, University and Hospital Trust of Verona, Verona, Italy.
Giampaolo TortoraDepartment of Medicine, Section of Medical Oncology, University and Hospital Trust of Verona, Verona, Italy.
Emilio BriaDepartment of Medicine, Section of Medical Oncology, University and Hospital Trust of Verona, Verona, Italy.
Gabriella FontaniniDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Marco VolanteDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Torino, Italy.
Aldo ScarpaARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
University of Verona · ITAzienda Ospedaliera Universitaria Pisana · ITMartin University · USOspedale Policlinico San Martino · ITOspedale San Luigi Gonzaga · ITUniversity of Milan · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNETs) comprising the four World Health Organization classification categories: 53 typical carcinoid (TCs), 35 atypical carcinoid (ACs), 27 large-cell neuroendocrine carcinomas, and 33 small-cell lung carcinomas. A discovery screen was conducted on 46 samples by the use of whole-exome sequencing and high-coverage targeted sequencing of 418 genes. Eighty-eight recurrently mutated genes from both the discovery screen and current literature were verified in the 46 cases of the discovery screen, and validated on additional 102 LNETs by targeted NGS; their prevalence was then evaluated on the whole series. Thirteen of these 88 genes were also evaluated for copy number alterations (CNAs). Carcinoids and carcinomas shared most of the altered genes but with different prevalence rates. When mutations and copy number changes were combined, MEN1 alterations were almost exclusive to carcinoids, whereas alterations of TP53 and RB1 cell cycle regulation genes and PI3K/AKT/mTOR pathway genes were significantly enriched in carcinomas. Conversely, mutations in chromatin-remodelling genes, including those encoding histone modifiers and members of SWI-SNF complexes, were found at similar rates in carcinoids (45.5%) and carcinomas (55.0%), suggesting a major role in LNET pathogenesis. One AC and one TC showed a hypermutated profile associated with a POLQ damaging mutation. There were fewer CNAs in carcinoids than in carcinomas; however ACs showed a hybrid pattern, whereby gains of TERT, SDHA, RICTOR, PIK3CA, MYCL and SRC were found at rates similar to those in carcinomas, whereas the MEN1 loss rate mirrored that of TCs. Multivariate survival analysis revealed RB1 mutation (p = 0.0005) and TERT copy gain (p = 0.016) as independent predictors of poorer prognosis. MEN1 mutation was associated with poor prognosis in AC (p = 0.0045), whereas KMT2D mutation correlated with longer survival in SCLC (p = 0.0022). In conclusion, molecular profiling may complement histology for better diagnostic definition and prognostic stratification of LNETs. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

AdultAgedCarcinoid TumorCarcinoma, NeuroendocrineChromatin Assembly and DisassemblyCohort StudiesDNA-Binding ProteinsDNA Copy Number VariationsFemaleHigh-Throughput Nucleotide SequencingHumansItalyLung NeoplasmsMaleMiddle AgedMutationDNA-Binding ProteinsKMT2D protein, humanMEN1 protein, humanNeoplasm ProteinsProto-Oncogene ProteinsRB1 protein, humanRetinoblastoma Binding ProteinsTelomeraseTERT protein, humanUbiquitin-Protein Ligasesexome sequencingKMT2Dlung tumoursMEN1neuroendocrineRB1targeted sequencingTERT

Identifiers

PMID27873319
PMCPMC5324596
OpenAlexW2611497676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.